Kilitch Drugs (India) Limited has informed the Exchange regarding Board meeting held on August 25, 2025.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs (India) Limited has completed its Rights Issue with the board approving the allotment of 13,98,463 equity shares of face value Rs. 10 each to eligible shareholders at an issue price of Rs. 357 per share, including a premium of Rs. 347. The allotment was made as per the Letter of Offer dated July 12, 2025, with MUFG Intime India as the registrar. Post-allotment, the company's paid-up equity share capital has increased from 1,60,82,319 shares to 1,74,80,782 shares, reflecting roughly an 8.7% expansion in share count.
The rights issue is now complete and shares have been allotted. Existing shareholders who did not subscribe will see their effective ownership diluted. The new capital raised should strengthen the company's balance sheet for future operations or growth plans.